Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tubulin-interacting agents. Epilogue.

J Fahy1, B T Hill

  • 1Division de Chimie Medicinale V, Centre de Recherche Pierre Fabre, Castres, 81106, France. jacques.fahy@pierre-fabre.com

Current Pharmaceutical Design
|July 27, 2001
PubMed
Summary

Researchers are identifying new tubulin-interacting compounds from natural and synthetic sources. These novel small molecules, including microtubule stabilizers and Vinca alkaloid site agents, show promise in pharmaceutical development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Cell death & disease·2024
Same author

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection.

Bone marrow transplantation·2017
Same author

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

Bone marrow transplantation·2016
Same author

Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

Bone marrow transplantation·2016
Same author

Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Leukemia·2015

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Tubulin is a key target for cancer therapeutics.
  • Numerous natural products and synthetic compounds interact with tubulin.
  • New tubulin-targeting agents are continuously being discovered.

Purpose of the Study:

  • To review and categorize newly identified tubulin-interacting compounds.
  • To highlight their diverse origins and mechanisms of action.
  • To discuss their potential in pharmaceutical development.

Main Methods:

  • Literature review of recent findings on tubulin-interacting compounds.
  • Classification of compounds based on their mechanism of action.
  • Analysis of their sources (natural, combinatorial chemistry).

Related Experiment Videos

Main Results:

  • Identification of several new families of small molecules targeting tubulin.
  • These compounds originate from natural sources and synthetic chemistry.
  • Compounds are mechanistically classified into microtubule stabilizers, Vinca alkaloid site agents, and colchicine site binders.

Conclusions:

  • A growing number of tubulin-interacting agents are available for pharmaceutical development.
  • These agents exhibit diverse mechanisms, offering multiple therapeutic strategies.
  • Continued research into novel tubulin modulators is crucial for drug discovery.